Summary. The binding affinity for the insulin receptor was determined with a variety of insulin derivatives and compared to the biological activity in vitro and in vivo and to the physical properties of the derivatives. The relative binding affinity of each derivative was measured in a specific insulin-receptor binding system using mono 12~I-insulin and purified plasma membranes of rat liver. Twenty one chemically modified insulins were investigated, including acetylinsulins, crosslinked insulin dimer and insulin trimer, and insulins with an A~--B~ or A~--B29 intra-moleeular crosslink. The relative binding affinity corresponded to the relative biological potency in vitro for all of the derivatives studied. There was a good agreement between the activity in vitro and the physical properties as measured by circular dichroism spectroscopy with the acetylinsulins and with the crosslinked insulin monomer, dimer and trimer. In contrast, with most of the derivatives possessing an intra-molecular erosslink, the very reduced binding affinity (0.2--5.90/o) and the comparably reduced biological potency in vitro opposed the moderate changes in physical properties. Biological activity was consistently higher in vivo than in vitro.
The insulin specific binding system developed with mono 125I-insu]in [12] and purified liver plasma membranes [9--13] permits direct measurements of the affinity of an insulin analogue or of a chemically modified inslllin for the insulin specific receptors. In earlier studies with insulins and insulin analogues that included proinsulin, A and B chains of insulin and insulins from various animal species, we observed that the ability to inhibit the 125I-insulin binding to receptor was, in all cases, directly proportional to the biological activity in vitro [13] .
In the present study, we have measured the affinity of chemically modified insulins for the insulin receptor in the liver plasma membrane. The derivatives investigated offer a wide range of chemical modification. Our purpose was to compare their binding affinity to their biological activity in vitro and in vivo and to their physical properties, as measured by circular dichroism (CD) spectroscopy. Some derivatives feature an intramolecular crosslink between the Gly A 1 a amino and the Lys B29 e amino groups. Because these two amino groups are close to each other in the crystal structure [1, 2] and because the A1--B29 crosslinked derivatives resemble proinsulin in several respects, it was of particular interest to see how suchintramolecnlar crosslinks would affect the binding affinity for the insulin receptor.
Materials and Methods
Chemically Modified Insulin (Fig. 1) Insulin derivatives were prepared by reacting beef insulin (obtained from Brunnengr~ber, Lfibeek, 25 IU/ mg) with mono-and bifunctional reagents and purified to give homogenous preparations. All substitutions were on the amino groups only. Amorphous standard beef insulin was obtained by gel filtration of the crystalline commercial product on Sephadex G-50 fine in 10~o acetic acid, dialysis of the main fraction against water and reprecipitation of the lyophilized product from 0.005--0.01 N ammonia/tiC1 at pH 5.4.
The preparation of A1, Be9-diaeetylinsulin and A1, B 1, B29-triaeetylinsulin has been described elsewhere [6] . Insulin monomer (A1--B1) , dimer (B1--B~) and trimer (B1--B~, A~--B~') were prepared [5] with the bifunctional Edman reagent m-phenylene-diisothioeyanate (PBC).
Twelve derivatives intramoleeularly crosslinked with aliphatic dicarboxylic acid residues--CO-(CH 2)m-CO-between the Gly A 1 a amino and the Lys B29 e amino groups [3, 4, 7] were investigated. Depending on the total number of C-atoms (n = m-~ 2, ranging from 2 to 13) present in the crosslink, they realize various chain lengths (about 2--16 A if fully extended) between the amino groups of glycine A 1 and lysine B29.
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Two derivatives were crosslinked with undeeane (n = 11) and dodeeane (n = 12) diacid residues between the N-terminal amino groups Of Gly Az and Phe B~.
Physical properties studied by CD spectroscopy and biological activity, as measured in vivo by blood sugar depression in rats [18] and in vitro by glucose oxidation in isolated fat cells [14] , were determined on these insulin derivatives [3--7, 15] . 
Receptor-Binding Assay of Chemically Modified Insulins
The insulin-receptor binding system consisted of mono l~SI-poreine insulin and purified plasma membranes from rat liver [9--13] . This in vitro system permits direct and quantitative measurements of the specific binding of insulin to its receptors with insulin concentrations as low as 0.05--1.0 nM. The inhibiting effects of insulin derivatives on the binding of l~sI-insulin to the plasma membrane were compared to effect of unlabelled native insulin.
Purified "mono component" porcine insulin (MCS 970, 27.2 IU/mg), kindly supplied by Dr J. Schlichtkrull (Nero l~eseareh Institute, Copenhagen, Denmark), was used for iodination and as the reference native hormone in the binding experiments. Mono 125I-insulin was prepared and purified on DEAE cellulose as described previously [12] , except that urea was omitted from the eluting buffer. Specific activities of approx. 350 FCi/Fg (~ 2000 Ci/mmole, or 0.9 I atom/mole of insulin) were achieved. Plasma membranes were prepared from rat livers according to Neville [16] ; the fully purified plasma membrane fraction (step 15 in ref. 16 ) was used in all experiments.
Binding assays were performed at 30~ for 30 rain 1 with membrane protein at 0.2--0.3 mg/ml incubation medium and 1.5~o bovine serum albumin (Fraction V, Pentex), in Krebs Ringer phosphate buffer, pH 7.5; under these conditions, degradation of insulin [9] was less than i5%. l~5I-insulin at 0.1 nM was incubated with membranes in the absence and in the presence of various concentrations of unlabelled insulin or derivative (Fig. 2) . The membrane-bound 125I-insulin was isolated by rapid centrifugation at 4 ~ as described previously [13] .
Each derivative was tested at 3--6 concentrations within a single experiment and reassayed in 3--8 different experiments. Native insulin was tested (as the reference preparation) at least twice in any single experiment. The concentration of any given derivative that produced 50 % inhibition of the 125I-insulin binding was taken to express the binding affinity of the derivative relative to that of native insulin. Thus, the binding affinity of a derivative molar concentration of porcine insulin to achieve molar concentration of derivative 50% inhibiting effect • 100 %. 
Results
Data obtained in the receptor-binding assay are shown in Fig. 2 . Comparison between the binding affinity and the biological activity is giveu in Tables 1  and 2. 1 Similar data were obtained when incubations were performed for 60 rain With the diaeetyl and the triaeetylinsulins, the reduction in binding affinity (25% and 8~o that of native insulin, respectively) was similar to the reduction in bio]ogicM potency in vitro, but contrasted with the apparent full retention of activity in vivo. It is of interest that the PBC-insulin dimer retained, on a monomer units in the trimer retains substantial activity.
Insulin derivatives that possess an intramolecular crosslink all exhibited a considerably reduced binding affinity. This was observed with the A1--B 1 as well as with the Ai--B29 crosslinked derivatives. With the molar basis, almost 50% of the affinity and potency in vitro of the insulin monomer, suggesting that one of the two insulin molecules in this dimer is almost fully active. It is also remarkable that the PBC2-insulin trimer, a rather large molecule, retained about 15% of the affinity and potency in vitro of the native insulin monomer, again indicating that at least one of the latter, the relative binding affinity ranged from 0.8% with the suceinyl to 5.9~o with the diaminosuberoylderivative (Tables 1 and 2 ). The binding affinity increased slightly but significantly (0.01 < p < 0.02) with the length of the bridge from the suecinyl to the sebaeoyl derivative ( Table 1 ). The increase in binding affinity was also significant (0.01 < p < 0.02) between the sueeinyl and the suberoyl derivative. In the latter, the A1--B29 chain length corresponds, if fully extended, to the erystMlographie distance (8--10 ~) between the connected sites [1] ; however, the suberoyl-derivative had only 1[.5% of the binding affinity of native insulin (Table 1) . It is of interest that the diaminosuberoyl-derivative exhibited a higher binding affinity titan that of the subcroyl-derivative ( Table 2 ). The diaminosuberoylinsulin had the highest relative binding affinity (5.9%) amongst all of the A1--B~9 erosslinked derivatives studied. Blocking the free amino groups of tile diaminosuberoyl-derivative with butyl-oxy-earbonyl (Bee) 1" decreased the binding affinity down to that observed with the suberoyl-derivative ( Table 2 ), indicating that free amino groups may be important, either directly or indirectly, in the receptor-binding process. Reduced-reoxidized diaminosuberoyl-insulin was almost as active as diaminosuberoyl-insulin (Table 2) . This finding complements, at the membrane receptor level, recent observations with adipoyl-insulin which suggest that A1--B~9 crosslinked derivatives behave similarly to proinsulin with respect to the ability to readopt the original conformation after reduction and reoxidation [7] .
With all of the intramoleeularly crosslinked derivatives, the relative binding affinity was either in close correspondence or, in most instances, lower than the relative biological potency in vitro (Tables 1 and 2 ). In contrast to in vitro data, the biological activity of the A1--B~9 crosslinked insulins appeared to be largely retained in vivo (Table 1) .
Discussion
conformationM change possibly required for binding to the receptor.
The discrepancy between the loss of activity in vitro and the apparent retention of activity in vivo is another striking feature of the A1--B29 crosslinked insulins. In vitro studies allow one to measure the affinity for the receptor, and the potency and the efficacy throughout a wide range of concentration of the hormone or derivative; degradation of the hormone or derivative can be minimized or controlled. In rive data reflect an overall effect which results from several processes: in addition to the potency and the efficacy, distribution and degradation may differ amongst the various derivatives when compared to insulin. For example, the slower degradation rate of proinsulin appears to be responsible, at least in part, for its longer half-life [i7] and prolonged activity in vivo [8] , and may account for its higher relative activity in vivo than in vitro when compared to insulin. It is possible that similar differenees can explain the higher activity in rive than in vitro observed here with the A~--B29 crosslinked derivatives.
Since most of the chemically modified insulins used in this study presented a very reduced biological potency in vitro, it was of interest to examine directly, in the insulin receptor-binding system, the possibility that some of them might have retained a binding affinity "in excess" of their reduced biological potency and could thus behaveas antagonist(s) of insulin. This was not found to be the case, and all of them appeared to behave as insulin agonists of lower potency, These data thus extend to the various derivatives studied here our previous findings with other insulins and insulin analogues [10, 13] . They also indicate that the changes induced by the present chemical modifications do not disclose discrete regions of the structure that would be separately responsible for binding to receptor and for activating cellular processes once the hormonereceptor complex has been formed.
There was a good agreement between the data obtained in vitro and the physical properties as studied by CD spectroscopy [4, 5] with the aeetylinsulins and with the insulin monomer, dimer and trimer. In contrast, the A1--B 1, and even more strikingly the A1--B~ crosslinked derivatives all exhibited a very reduced binding affinity and biological potency in vitro that opposed the moderate changes in their CD spectra [4] . A1--B~9 erosslinked insulins resemble proinsulin in several respects: they behave as insulin agonists of very low potency in vitro and are capable of readopting their original properties after reduction and reoxidation (Table 2 and ref. 7) . It is possible that, somewhat similarly to the connecting peptide in the proinsulin molecule [11] , the Miphatie erosslink between Gly A 1 and Lys B29 may alter or hinder, in the vicinity of Gly A 1, a region of the insulin molecule [1, 2] which is likely to be involved in binding to the receptor. In addition, or alternatively, such a link could impede a
